The results showed that NRP1 expression was also correlated with overall (HR, 1.65; 95% CI, 1.07–2.54; P=0.02), and disease specific 5-year survival (HR, 1.64; 95% CI, 1.06–2.53; P=0.03) in patients with metastatic melanoma (Table III). Here, NRP1 is linked to metastatic melanoma.